Notícias e Atividades da Revance

Revance é uma empresa listada sob o símbolo RVNC (US).

Eles estão dentro:

• Biotecnologia33%
• Farmacêutica33%
• Outro33%

Fusão, aquisição e financiamento envolvendo Revance.

• Crown Laboratories adquiriu Revance (publicado em 9 de fevereiro de 2025).
• Revance has announced the acquisition of Revance  (publicado em 14 de janeiro de 2025).
• Crown Laboratories and Revance have announced they will merge  (publicado em 14 de agosto de 2024)..

Veja o organograma con seus 47 executivos principais

Biografias mais buscadas da Revance

• Nadeem Moiz, Chief Executive Officer
• William Meury, Director
• Jeff Bedard, Executive Chairman of the Board

Recentes movimentos de executivos em Revance

• Michael Mckenna, Executive Vice President and Chief Sales Officer, Aesthetics, deixou a Companhia  (Notícia publicada em 3 de abril de 2026).
• Steve Kreider, ingressou na Companhia como Executive Vice President, Chief Revenue Officer  (Notícia publicada em 12 de janeiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Revance.

Revance possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Revance

• Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Revance Therapeutics, Inc.
• Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference - Revance Therapeutics, Inc.
• Revance to Participate in the William Blair 42nd Annual Growth Stock Conference - Revance Therapeutics, Inc.
• Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update - Revance Therapeutics, Inc.
• Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022 - Revance Therapeutics, Inc.
• Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting - Revance Therapeutics, Inc.
• Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Revance Therapeutics, Inc.
• Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference - Revance Therapeutics, Inc.
• Revance to Participate in the Wells Fargo Securities Healthcare Conference - Revance Therapeutics, Inc.
• Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers - Revance Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Revance

• Revance na Wikipedia, Google News e Yahoo Finance
• Revance na LinkedIn, X (Twitter) e YouTube